| | Study | Dosage | Duration | Outcome | | Control group | Trial group |
| | Peifeng, 2015 [15] | NF (2 times/d, 30 mg/times) | TGD (52.5 g/times, 2∼3 times/d) + NF (2 times/d, 30 mg/times) | 1 month | Ae | | Xiaofei et al., 2016 [16] | NF (1 times/d, 30 mg/times) | TGD (51.2 g/times, 2∼3 times/d) + NF (1 times/d, 30 mg/times) | 2 weeks | Ae TCMS | | Tao, 2016 [17] | NF (2 times/d, 10 mg/times) | TGD (48.4 g/times, 2∼3 times/d) + NF (2 times/d, 10 mg/times) | 8 weeks | BP Scr BUN | | Yingke, 2014 [18] | NFS (2 times/d, 10 mg/times) | TGD (52 g/times, 2∼3 times/d) + NFS (2 times/d, 10 mg/times) | 2 weeks | Ae TCMS | | Jinbo, 2015 [19] | NFS (2 times/d, 10 mg/times) | TGD (57 g/times, 2 times/d) + NFS (2 times/d, 10 mg/times) | 2 weeks | Ae | | Fan and Lili, 2015 [20] | NFS (1 times/d, 5 mg/times) | TGD (87.5 g/times 2 times/d) + NFS (1 times/d, 5 mg/times) | 3 months | Ae | | Pan, 2019 [21] | NFS (1 times/d, 20 mg/times) | TGD (90 g/times, 2 times/d) + NFS (1 times/d, 20 mg/times) | 2 weeks | BP | | Xiaofang, 2016 [22] | NFS (2 times/d, 20 mg/times) | TGD (125 g/d) + NFS (2 times/d, 20 mg/times) | NR | Ae BP Ar | | Fu, 2018 [23] | NFS (2 times/d, 20 mg/times) | TGD (57 g/times, 2 times/d) + NFS (2 times/d, 20 mg/times) | 6 months | Ae BP Ar | | Caihong, 2017 [24] | NFS (1 times/d, 30 mg/times) | TGD (79 g/times, 2 times/d) + NFS (1 times/d, 30 mg/times) | NR | Ae BP | | Dai, 2019 [25] | NF (1 times/d, 20 mg/times) | TGD (NR) + NF (1 times/d, 20 mg/times) | 2 weeks | Ae BP Ar | | Yugao, 2017 [26] | NFS (2 times/d, 10 mg/times) | TGD (52 g/times, 3 times/d) + NFS (2 times/d, 10 mg/times) | 8 weeks | Ae BP life quality | | Peng et al., 2016 [27] | NFC (1 times/d, 30 mg/times, after half a month, 2 times/d, 30 mg/times) | TGD (46.7 g/times 2 times/d) + NFC (1 times/d, 30 mg/times, after half a month, 2 times/d, 30 mg/times) | 2 months | Ae BP | | Yingjun, 2015 [28] | NFS (2 times/d, 10 mg/times) | TGD (68.8 g/times, 3 times/d) + NFS (2 times/d, 10 mg/times) | NR | Ae BP |
|
|
